Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnara Pharmaceuticals, a developer of protein therapeutics, has signed a licensing agreement with the Cystic Fibrosis Foundation Therapeutics, the nonprofit affiliate of the Cystic Fibrosis Foundation, for the worldwide rights to liprotamase, a novel, oral, porcine-free pancreatic enzyme replacement therapy that has already completed a Phase III efficacy trial.
Subscribe to our email newsletter
Under the terms of the agreement Alnara will obtain exclusive worldwide rights to develop and market liprotamase.
Robert Beall, president and CEO of the Cystic Fibrosis Foundation Therapeutics (CFFT), said: “The Cystic Fibrosis Foundation is excited to enter into a licensing agreement with Alnara for the development of liprotamase, which has the potential to be the first porcine-free pancreatic enzyme therapy for cystic fibrosis patients with pancreatic insufficiency.
“We look forward to working with Alnara to quickly finish the development of liprotamase and bring this promising new treatment option to patients with cystic fibrosis.”